In The Press: IPWATCHDOG Turns to Partner Charles R. Macedo for his Insights on SCOTUS decision in Sandoz v. Amgen over Biosimlar Drugs

Industry Reaction to SCOTUS decision in Sandoz v. Amgen By Gene Quinn   Charles R. Macedo Amster Rothstein & Ebenstein LLP In Sandoz v. Amgen, the Supreme Court addressed the “plain language” of a “carefully crafted and detailed enforcement scheme” relating to “biologic” drugs. Under this complex statute that was enacted as part of ObamaCare as […]

Patent Law Alert:
SUPREME COURT CLARIFIES THE RULES FOR BIOSIMILARS

(June 12, 2017)  In Sandoz v. Amgen, 582 U. S. ___ (2017), the Supreme Court addressed the “plain language” of a “carefully crafted and detailed enforcement scheme” relating to “biologic” drugs. Under this complex statute that was enacted as part of ObamaCare as an effort to get generic biosimilar and interchangeable biologic drugs on the market quicker […]